Semax and Anti-Glutamate Antibodies Protect Brain from Ischemic Damage

Brain ischemia, a condition where blood flow to the brain is restricted, particularly in the prefrontal cortex, can lead to significant neuronal damage and severe cognitive deficits like amnesia. Developing effective neuroprotective agents is crucial for mitigating these devastating effects and improving patient outcomes. This study aimed to compare the neuroprotective and anti-amnesic actions of the peptide Semax and antibodies to glutamate (AB-Glu) in a rat model of focal brain ischemia.

Both Semax and AB-Glu treatments resulted in a pronounced diminishing of cortex damage volume in the ischemic prefrontal cortex compared to control animals, indicating significant neuroprotection. Furthermore, both interventions demonstrated a significant relief in the preservation and reproduction of the rat passive avoidance reflex, which is a behavioral measure of memory and learning, thereby showing pronounced antiamnestic action after the ischemic event. The study found that intranasal administration of both Semax and AB-Glu effectively diminished the cortex damage volume and provided pronounced relief in the preservation and reproduction of the passive avoidance reflex following ischemic injury. While specific quantitative percentages or p-values were not provided in the abstract, the observed neuroprotective and antiamnestic effects were consistently described as pronounced and significant for both treatments, indicating a clear therapeutic benefit.